Hepatitis B virus (HBV) infection, defined as surface antigen positivity (HBsAg+), has been confirmed to be strongly associated with increased incidence risk and poor prognosis of B-cell lymphoma. To address clinical needs, we propose a novel prognostic scoring system that integrates HBV-related factors and immune-regulatory biomarkers, which demonstrates superior reliability in identifying high-risk patients compared to the conventional FLIPI (Follicular Lymphoma International Prognostic Index). This dataset represents the animal model data matrix related to the study.